|
1
|
Hart S, Horsman JM, Radstone CR, Hancock
H, Goepel JR and Hancock BW: Localised extranodal lymphoma of the
head and neck: The sheffield lymphoma group experience (1971–2000).
Clin Oncol (R Coll Radiol). 16:186–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wallace C, Ramsay AD and Quiney RE:
Non-Hodgkin's extranodal lymphoma: A clinico-pathological study of
24 cases involving head and neck sites. J Laryngol Otol.
102:914–922. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akhtar S, Khafaga Y, Edesa W, Al-Mubarak
M, Rauf MS and Maghfoor I: Hodgkin lymphoma involving extranodal
sites in head and neck: Report of twenty-nine cases and review of
three-hundred and fifty-seven cases. Hematology. 26:103–110. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo J, Huang F, Zhou P, Chen J, Sun Y, Xu
F, Wu L and Huang P: Is ultrasound combined with computed
tomography useful for distinguishing between primary thyroid
lymphoma and Hashimoto's thyroiditis? Endokrynol Pol. 70:463–468.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stein SA and Wartofsky L: Primary thyroid
lymphoma: A clinical review. J Clin Endocrinol Metab. 98:3131–3138.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chapuy B, Stewart C, Dunford AJ, Kim J,
Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et
al: Molecular subtypes of diffuse large B cell lymphoma are
associated with distinct pathogenic mechanisms and outcomes. Nat
Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Graff-Baker A, Sosa JA and Roman SA:
Primary thyroid lymphoma: A review of recent developments in
diagnosis and histology-driven treatment. Curr Opin Oncol.
22:17–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaker L, Bianco AC, Jonklaas J and
Peeters RP: Hypothyroidism. Lancet. 390:1550–1562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ralli M, Angeletti D, Fiore M, D'Aguanno
V, Lambiase A, Artico M, de Vincentiis M and Greco A: Hashimoto's
thyroiditis: An update on pathogenic mechanisms, diagnostic
protocols, therapeutic strategies, and potential malignant
transformation. Autoimmun Rev. 19:1026492020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weetman AP: An update on the pathogenesis
of Hashimoto's thyroiditis. J Endocrinol Invest. 44:883–890. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ragusa F, Fallahi P, Elia G, Gonnella D,
Paparo SR, Giusti C, Churilov LP, Ferrari SM and Antonelli A:
Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and
therapy. Best Pract Res Clin Endocrinol Metab. 33:1013672019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Travaglino A, Pace M, Varricchio S,
Insabato L, Giordano C, Picardi M, Pane F, Staibano S and Mascolo
M: Hashimoto thyroiditis in primary thyroid non-hodgkin lymphoma.
Am J Clin Pathol. 153:156–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu M, Shu J, Qian S, Guo J, Gong Y, Huang
R, Wang S, Zhou Z, Yuan G, Huang M, et al: Zuberitamab, an
innovative anti-CD20 monoclonal antibody, for patients with primary
immune thrombocytopenia in China: A randomized, double-blind,
placebo-controlled, phase 2 study. Lancet Reg Health West Pac.
47:1010962024.PubMed/NCBI
|
|
16
|
Vardell Noble V, Ermann DA, Griffin EK and
Silberstein PT: Primary thyroid lymphoma: An analysis of the
national cancer database. Cureus. 11:e40882019.PubMed/NCBI
|
|
17
|
Holm LE, Blomgren H and Löwhagen T: Cancer
risks in patients with chronic lymphocytic thyroiditis. N Engl J
Med. 312:601–604. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Derringer GA, Thompson LD, Frommelt RA,
Bijwaard KE, Heffess CS and Abbondanzo SL: Malignant lymphoma of
the thyroid gland: A clinicopathologic study of 108 cases. Am J
Surg Pathol. 24:623–639. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thieblemont C, Mayer A, Dumontet C,
Barbier Y, Callet-Bauchu E, Felman P, Berger F, Ducottet X, Martin
C, Salles G, et al: Primary thyroid lymphoma is a heterogeneous
disease. J Clin Endocrinol Metab. 87:105–111. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Jiang W, Zhou H, Cen H, Zhang M, Lv
F, Zhang Q, Sun X, Liu L, Huang Y, et al: Comparison of zuberitamab
plus CHOP versus rituximab plus CHOP for the treatment of
drug-naïve patients diagnosed with CD20-positive diffuse large
B-cell lymphoma: A phase 3 trial. J Immunother Cancer.
12:e0088952024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Advani RH, Buggy JJ, Sharman JP, Smith SM,
Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et
al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has
significant activity in patients with relapsed/refractory B-cell
malignancies. J Clin Oncol. 31:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herbaux C, Bachy E, Bouabdallah R, Guidez
S, Casasnovas O, Feugier P, Damaj G, Tilly H, Ysebaert L, Le Gouill
S, et al: Atezolizumab, obinutuzumab and venetoclax for the
treatment of patients with relapsed/refractory B non-Hodgkin
lymphoma: Final analysis of a phase II trial from the LYSA group.
Br J Haematol. 207:110–122. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davids MS, Roberts AW, Seymour JF, Pagel
JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH,
et al: Phase I first-in-human study of venetoclax in patients with
relapsed or refractory non-hodgkin lymphoma. J Clin Oncol.
35:826–833. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dickinson MJ, Carlo-Stella C, Morschhauser
F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F,
Trněný M, et al: Glofitamab for relapsed or refractory diffuse
large B-cell lymphoma. N Engl J Med. 387:2220–2231. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schuster SJ, Bishop MR, Tam CS, Waller EK,
Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin
JR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse
large B-cell lymphoma. N Engl J Med. 380:45–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bergsma P, Riemenschnitter C,
Gruber-Mösenbacher U and Brand Y: Primary Burkitt lymphoma of the
thyroid associated with Hashimoto's thyroiditis. BMJ Case Rep.
15:e2460082022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Watanabe N, Noh JY, Narimatsu H, Takeuchi
K, Yamaguchi T, Kameyama K, Kobayashi K, Kami M, Kubo A, Kunii Y,
et al: Clinicopathological features of 171 cases of primary thyroid
lymphoma: A long-term study involving 24553 patients with
Hashimoto's disease. Br J Haematol. 153:236–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Su MW, Beck TN, Knepprath J, Romero-Velez
G, Heiden KB and McHenry CR: Primary thyroid lymphoma: A
multi-center retrospective review. Am J Surg. 237:1159272024.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu S, Luo Q and Zeng S: Diagnostic
challenges of primary thyroid lymphoma: A case report. Asian J
Surg. 47:1857–1858. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sharma A, Jasim S, Reading CC, Ristow KM,
Villasboas Bisneto JC, Habermann TM, Fatourechi V and Stan M:
Clinical presentation and diagnostic challenges of thyroid
lymphoma: A cohort study. Thyroid. 26:1061–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karabachev AD, Brundage WJ, Sajisevi MB
and Ciolino AL: Feasibility of fine needle aspiration for diagnosis
of b-cell lymphoma of the thyroid: A case series and review of the
literature. Diagn Pathol. 18:692023. View Article : Google Scholar : PubMed/NCBI
|
